US Edition
Published • loading... • Updated
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving High
Biogen’s $5.6 billion acquisition of Apellis includes contingent payments tied to Syfovre sales, with combined drug sales reaching $689 million in 2025, boosting growth in immunology and rare diseases.
- On Tuesday, Biogen announced it will acquire Apellis Pharmaceuticals for an upfront payment of around $5.6 billion, valuing the company at $41 per share, representing a premium of about 140% to the stock's last close.
- Facing competition from biosimilars to its multiple sclerosis drugs Tysabri, Tecfidera, and Spinraza, Biogen is bolstering its rare-disease portfolio through the acquisition. The deal accelerates Biogen's entry into nephrology and kidney disease treatments.
- Apellis brings two FDA-approved therapies to Biogen's portfolio: Empaveli and Syfovre. Combined net sales for these products reached $689 million in 2025 and are expected to grow at a mid-to-high teens rate through 2028.
- Shareholders remain eligible for up to an additional $4 per share through contingent value rights tied to Syfovre sales milestones. Payments include $2 for annual sales reaching $1.5 billion and $2 for crossing the $2 billion threshold.
- Biogen CEO Chris Viehbacher stated, "This acquisition immediately advances Biogen's ongoing transformation," expecting a "significant proportion" of Apellis employees to join the company. The deal positions Biogen to strengthen its immunology and rare-disease capabilities.
Insights by Ground AI
10 Articles
10 Articles
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving High
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave Life, Perimeter Solutions, Praxis Precision, and Century Aluminum.
·New York, United States
Read Full Article
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal diseaseBringing together Biogen and Apellis’ commercialization capabilities will maximize the…
·Hamilton, Canada
Read Full ArticleCoverage Details
Total News Sources10
Leaning Left1Leaning Right0Center5Last UpdatedBias Distribution83% Center
Bias Distribution
- 83% of the sources are Center
83% Center
L 17%
C 83%
Factuality
To view factuality data please Upgrade to Premium
